

AMENDMENTS TO THE CLAIMS:

*The following listing replaces all prior versions of the claims:*

1. (Currently amended) A composition comprising a loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or its pharmaceutically acceptable salts ~~glucocorticoid and at least one phosphodiesterase 4 inhibitor~~ in fixed or free combination.
- 2-4. (Canceled)
5. (Currently amended) The composition as claimed in claim [[3]] 1, characterized in that ~~the glucocorticoid is~~ it contains loteprednol etabonate.
6. (Currently amended) A medicament for the treatment of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases, comprising as active ingredient a ~~glucocorticoid and at least one phosphodiesterase 4 inhibitor~~ loteprednol or a pharmaceutically acceptable salt thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or its pharmaceutically acceptable salts in fixed or free combination, where appropriate together with customary excipients or carriers.
7. (Original) The medicament as claimed in claim 6, characterized in that it can be administered orally.
8. (Original) The medicament as claimed in claim 6, characterized in that it can be administered topically.
9. (Original) The medicament as claimed in claim 8, characterized in that it can be administered simultaneously, sequentially or separately from one another, intranasally or by inhalation.
10. (Currently amended) The medicament as claimed in claim 8, characterized in that it is an inhalable liquid or solid preparation.
11. (Original) The medicament as claimed in claim 6, characterized in that one active ingredient is administered orally and at least one active ingredient is administered topically.

12.(Original) The medicament as claimed in claim 6, characterized in that the phosphodiesterase-4 inhibitor(s) can be administered orally.

13. (Currently amended) A process for producing a medicament for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases, comprising as active ingredient a ~~glucocorticoid and at least one phosphodiesterase 4 inhibitor,~~ characterized in that the ~~glucocorticoid and the phosphodiesterase 4 inhibitor(s)~~ loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or its pharmaceutically acceptable salts are mixed singly or together, where appropriate together with customary excipients and carriers, and the mixture obtained in this way is converted into suitable dosage forms.

14. (Canceled)

15. (Canceled)

16. (New) The medicament as claimed in claim 9, characterized in that it is an inhalable liquid or solid preparation.

17. (New) A method for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases comprising the step of administering loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or a pharmaceutically acceptable salt thereof to a subject in need of treatment.